Sale!

MTAP Gene Diaphyseal Medullary Stenosis with Malignant Fibrous Histiocytoma Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The “MTAP Gene Diaphyseal Medullary Stenosis with Malignant Fibrous Histiocytoma Genetic Test” is a sophisticated diagnostic tool available at DNA Labs UAE, designed to identify mutations in the MTAP gene that are linked to diaphyseal medullary stenosis with malignant fibrous histiocytoma. This rare genetic condition is characterized by the narrowing of the medullary cavities of the long bones and the potential development of a highly aggressive form of cancer known as malignant fibrous histiocytoma. The test, which costs 4400 AED, plays a crucial role in the early detection and management of the disease, providing essential information for personalized treatment plans. By analyzing the patient’s DNA, the test helps in understanding the genetic basis of the condition, facilitating targeted therapies and informed clinical decisions. Conducted in the state-of-the-art facilities of DNA Labs UAE, this genetic test represents a significant advancement in the field of personalized medicine and genetic diagnostics.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

MTAP Gene Diaphyseal medullary stenosis with malignant fibrous histiocytoma Genetic Test

Test Name: MTAP Gene Diaphyseal medullary stenosis with malignant fibrous histiocytoma Genetic Test

Components: MTAP gene

Price: 4400.0 AED

Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card

Report Delivery: 3 to 4 Weeks

Method: NGS Technology

Test type: Osteology Dermatology Immunology Disorders

Doctor: Dermatologist

Test Department: Genetics

Pre Test Information: Clinical History of Patient who is going for MTAP Gene Diaphyseal medullary stenosis with malignant fibrous histiocytoma NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with MTAP Gene Diaphyseal medullary stenosis with malignant fibrous histiocytoma NGS Genetic DNA Test gene MTAP

Test Details:

MTAP gene is a tumor suppressor gene that is frequently deleted in various cancers. Diaphyseal medullary stenosis with malignant fibrous histiocytoma (DMS-MFH) is a rare bone disorder characterized by narrowing of the medullary cavity of long bones and the presence of malignant fibrous histiocytoma.

NGS (Next Generation Sequencing) genetic test refers to a high-throughput DNA sequencing technology that allows simultaneous sequencing of multiple genes or the entire genome. In the context of DMS-MFH, NGS genetic testing can be used to identify mutations or alterations in the MTAP gene and other relevant genes associated with the condition.

By analyzing the DNA sequence of the patient’s genes, NGS can help in diagnosing DMS-MFH and identifying specific genetic alterations that may be responsible for the development of the disease. This information can be useful for determining prognosis, selecting appropriate treatment options, and potentially identifying targeted therapies for patients with DMS-MFH.

Test Name MTAP Gene Diaphyseal medullary stenosis with malignant fibrous histiocytoma Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Osteology Dermatology Immunology Disorders
Doctor Dermatologist
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for MTAP Gene Diaphyseal medullary stenosis with malignant fibrous histiocytoma NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with MTAP Gene Diaphyseal medullary stenosis with malignant fibrous histiocytoma NGS Genetic DNA Test gene MTAP
Test Details

MTAP gene is a tumor suppressor gene that is frequently deleted in various cancers. Diaphyseal medullary stenosis with malignant fibrous histiocytoma (DMS-MFH) is a rare bone disorder characterized by narrowing of the medullary cavity of long bones and the presence of malignant fibrous histiocytoma.

NGS (Next Generation Sequencing) genetic test refers to a high-throughput DNA sequencing technology that allows simultaneous sequencing of multiple genes or the entire genome. In the context of DMS-MFH, NGS genetic testing can be used to identify mutations or alterations in the MTAP gene and other relevant genes associated with the condition.

By analyzing the DNA sequence of the patient’s genes, NGS can help in diagnosing DMS-MFH and identifying specific genetic alterations that may be responsible for the development of the disease. This information can be useful for determining prognosis, selecting appropriate treatment options, and potentially identifying targeted therapies for patients with DMS-MFH.